On Dec. 21, the FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria and approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Read more via U.S. Food & Drug Administration news release 1 and news release 2.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
